Hepatoid adenocarcinoma of the stomach effectively treated with capecitabine with oxaliplatin as adjuvant chemotherapy : A case report and literature review
Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved..
INTRODUCTION: Hepatoid adenocarcinoma of the stomach (HAS) is an alpha-fetoprotein (AFP)-producing gastric carcinoma (GC) with a hepatocellular carcinoma-like histology. HAS is a relatively rare type of GC, with liver metastases being more common than peritoneal dissemination in the recurrent form, and the poor prognosis.
PRESENTATION OF CASE: We present the case of a 70-year-old patient who underwent distal gastrectomy for GC and immunohistologically diagnosed as HAS. The patient had an intravenous tumor thrombus at the proximal margin of the resected stomach. Owing to the low possibility of radical resection and high probability of liver metastatic recurrence, capecitabine with oxaliplatin (CapeOX) was started as adjuvant chemotherapy (AC). After three courses of CapeOX, oxaliplatin was discontinued due to adverse events (peripheral neuropathy, grade3) and capecitabine alone was continued for 3 years postoperatively. Six years after surgery, no local recurrence or distant metastasis was detected on imaging studies.
DISCUSSION: There is no established standard treatment for HAS. Recently, some studies have reported the efficacy of antimetabolites or platinum-based drugs as AC regimens. We thus decided to start a regimen consisting of a combination of antimetabolites and a platinum, i.e., CapeOX, which proved efficacious.
CONCLUSION: CapeOX or capecitabine may be effective as AC for treating HAS.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:112 |
|---|---|
| Enthalten in: |
International journal of surgery case reports - 112(2023) vom: 15. Nov., Seite 108963 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Amioka, Jun [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
CapeOX |
|---|
| Anmerkungen: |
Date Revised 26.11.2023 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.ijscr.2023.108963 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363494103 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363494103 | ||
| 003 | DE-627 | ||
| 005 | 20231226211041.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijscr.2023.108963 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1211.xml |
| 035 | |a (DE-627)NLM363494103 | ||
| 035 | |a (NLM)37856969 | ||
| 035 | |a (PII)S2210-2612(23)01092-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Amioka, Jun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hepatoid adenocarcinoma of the stomach effectively treated with capecitabine with oxaliplatin as adjuvant chemotherapy |b A case report and literature review |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 26.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a INTRODUCTION: Hepatoid adenocarcinoma of the stomach (HAS) is an alpha-fetoprotein (AFP)-producing gastric carcinoma (GC) with a hepatocellular carcinoma-like histology. HAS is a relatively rare type of GC, with liver metastases being more common than peritoneal dissemination in the recurrent form, and the poor prognosis | ||
| 520 | |a PRESENTATION OF CASE: We present the case of a 70-year-old patient who underwent distal gastrectomy for GC and immunohistologically diagnosed as HAS. The patient had an intravenous tumor thrombus at the proximal margin of the resected stomach. Owing to the low possibility of radical resection and high probability of liver metastatic recurrence, capecitabine with oxaliplatin (CapeOX) was started as adjuvant chemotherapy (AC). After three courses of CapeOX, oxaliplatin was discontinued due to adverse events (peripheral neuropathy, grade3) and capecitabine alone was continued for 3 years postoperatively. Six years after surgery, no local recurrence or distant metastasis was detected on imaging studies | ||
| 520 | |a DISCUSSION: There is no established standard treatment for HAS. Recently, some studies have reported the efficacy of antimetabolites or platinum-based drugs as AC regimens. We thus decided to start a regimen consisting of a combination of antimetabolites and a platinum, i.e., CapeOX, which proved efficacious | ||
| 520 | |a CONCLUSION: CapeOX or capecitabine may be effective as AC for treating HAS | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a CapeOX | |
| 650 | 4 | |a Chemotherapy | |
| 650 | 4 | |a Hepatoid adenocarcinoma of the stomach | |
| 650 | 4 | |a Surgery | |
| 700 | 1 | |a Yanagawa, Senichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Yamamoto, Yuji |e verfasserin |4 aut | |
| 700 | 1 | |a Nakahara, Masahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Yonehara, Shuji |e verfasserin |4 aut | |
| 700 | 1 | |a Noriyuki, Toshio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of surgery case reports |d 2012 |g 112(2023) vom: 15. Nov., Seite 108963 |w (DE-627)NLM215724038 |x 2210-2612 |7 nnns |
| 773 | 1 | 8 | |g volume:112 |g year:2023 |g day:15 |g month:11 |g pages:108963 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijscr.2023.108963 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 112 |j 2023 |b 15 |c 11 |h 108963 | ||